CORT Stock Analysis: Corcept Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 8.564m USD | 12M Return: -6% | US2183521028 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 100M
EPS Trend: -48.8%
Qual. Beats: 2
Rev. Trend: 97.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Corcept Therapeutics Incorporated (NASDAQ: CORT) is a U.S.-based biopharmaceutical company founded in 1998 and headquartered in Redwood City, California. It focuses on discovering and developing treatments for serious endocrine, oncologic, metabolic, and neurologic disorders, with a distinctive scientific emphasis on cortisol modulation-a niche within the broader pharmaceuticals sector. Its commercial product, Korlym, is an oral therapy approved for hyperglycemia related to endogenous Cushings syndrome in adults with type 2 diabetes or glucose intolerance who are not surgical candidates or who have had unsuccessful surgery. The company is also advancing a pipeline of selective cortisol modulators-including relacorilant, miricorilant (in a Phase 1b trial for metabolic dysfunction-associated steatohepatitis, or MASH), nenocorilant, and dazucorilant-targeting indications ranging from hypercortisolism to amyotrophic lateral sclerosis (ALS).
As a commercial-stage biotech, Corcept generates revenue primarily from Korlym sales while reinvesting in clinical-stage pipeline assets-a common model among specialty biopharma peers that rely on a single approved drug to fund long-term R&D. Its large-cap market capitalization of roughly $12.4 billion reflects significant investor expectations for pipeline expansion beyond its flagship Cushings syndrome franchise.
- Relacorilant Phase 3 ROSELLA data in ovarian cancer approaches readout
- Korlym sales growth sustains amid expanding Cushings diagnosis rates
- Miricorilant Phase 2b MASH trial results expected later this year
| Net Income: 162.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.19 > 0.02 and ΔFCF/TA -0.92 > 1.0 |
| NWC/Revenue: 36.96% < 20% (prev 49.77%; Δ -12.80% < -1%) |
| CFO/TA 0.19 > 3% & CFO 198.1m > Net Income 162.0m |
| Net Debt (-361.7m) to EBITDA (134.4m): -2.69 < 3 |
| Current Ratio: 3.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (123.2m) vs 12m ago 3.15% < -2% |
| Gross Margin: 75.59% > 18% (prev 98.19%; Δ -22.60% > 0.5%) |
| Asset Turnover: 103.7% > 50% (prev 89.99%; Δ 13.76% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.34 (Total Current Assets 533.9m - Total Current Liabilities 177.7m) / Total Assets 1.03b |
| B: 0.76 (Retained Earnings 781.4m / Total Assets 1.03b) |
| C: 0.14 (EBIT TTM 131.4m / Avg Total Assets 928.8m) |
| D: 4.16 (Book Value of Equity 833.7m / Total Liabilities 200.3m) |
| Altman-Z'' = 10.05 = AAA |
| DSRI: 1.16 (Receivables 111.1m/73.5m, Revenue 963.6m/741.2m) |
| GMI: 1.30 (GM 98.19% / 75.59%) |
| AQI: 1.41 (AQ_t 0.47 / AQ_t-1 0.33) |
| SGI: 1.30 (Revenue 963.6m / 741.2m) |
| TATA: -0.03 (NI 162.0m - CFO 198.1m) / TA 1.03b) |
| Beneish M = -2.17 (Cap -4..+1) = BB |
As of November 14, 2026, the stock is trading at USD 72.94 with a total of 1,112,919 shares traded. Over the past week, the price has changed by +2.90%, over one month by -39.18%, over three months by -34.29% and over the past year by -5.97%.
Current recommended Stop Loss: 66.90 (which is 8.3% or 1.1 ATR below the current price).
Corcept Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CORT.
- StrongBuy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 141 | 93.3% |
P/E Trailing = 184.2326
P/E Forward = 14.5985
P/S = 10.3074
P/B = 12.603
P/EG = 0.813
Revenue TTM = 963.6m USD
EBIT TTM = 131.4m USD
EBITDA TTM = 134.4m USD
Long Term Debt = 6.97m USD (estimated: total debt 8.99m - short term 2.02m)
Short Term Debt = 2.02m USD (from shortTermDebt, last quarter)
Debt = 8.99m USD (from shortLongTermDebtTotal, last quarter) (leases 9.42m already included)
Net Debt = -361.7m USD (calculated: Debt 8.99m - CCE 370.7m)
Enterprise Value = 8.20b USD (8.56b + Debt 8.99m - CCE 370.7m)
Interest Coverage Ratio = unknown (Ebit TTM 131.4m / Interest Expense TTM 0.0)
EV/FCF = 42.14x (Enterprise Value 8.20b / FCF TTM 194.6m)
FCF Yield = 2.37% (FCF TTM 194.6m / Enterprise Value 8.20b)
FCF Margin = 20.20% (FCF TTM 194.6m / Revenue TTM 963.6m)
Net Margin = 16.81% (Net Income TTM 162.0m / Revenue TTM 963.6m)
Gross Margin = 75.59% ((Revenue TTM 963.6m - Cost of Revenue TTM 235.2m) / Revenue TTM)
Gross Margin QoQ = 33.70% (prev none%)
Tobins Q-Ratio = 7.93 (Enterprise Value 8.20b / Total Assets 1.03b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 8.99m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 103.8m (EBIT 131.4m * (1 - 21.00%))
Current Ratio = 3.00 (Total Current Assets 533.9m / Total Current Liabilities 177.7m)
Debt / Equity = 0.01 (Debt 8.99m / totalStockholderEquity, last quarter 833.7m)
Debt / EBITDA = -2.69 (Net Debt -361.7m / EBITDA 134.4m)
Debt / FCF = -1.86 (Net Debt -361.7m / FCF TTM 194.6m)
Total Stockholder Equity = 706.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 17.44% (Net Income 162.0m / Total Assets 1.03b)
RoE = 22.94% (Net Income TTM 162.0m / Total Stockholder Equity 706.3m)
RoCE = 18.43% (EBIT 131.4m / Capital Employed (Equity 706.3m + L.T.Debt 6.97m))
RoIC = 12.82% (NOPAT 103.8m / Invested Capital 810.2m)
WACC = 11.71% (E(8.56b)/V(8.57b) * Re(11.72%) + D(8.99m)/V(8.57b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.72% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 22.83 | Cagr: 4.64%
[DCF] Terminal Value 67.91% ; FCFF base≈181.8m ; Y1≈208.4m ; Y5≈306.7m
[DCF] Fair Price = 30.09 (EV 2.89b - Net Debt -361.7m = Equity 3.25b / Shares 108.1m; r=11.71% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -48.76 | EPS CAGR: -20.66% | SUE: 1.82 | # QB: 2
Revenue Correlation: 97.38 | Revenue CAGR: 23.61% | SUE: 0.16 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.91 | Chg30d=-6.19% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=2.13 | Chg30d=-0.78% | Revisions=-25% | GrowthEPS=+160.2% | GrowthRev=+51.3%
EPS next Year (2027-12-31): EPS=4.22 | Chg30d=-4.15% | Revisions=+0% | GrowthEPS=+97.8% | GrowthRev=+45.5%
[Analyst] Revisions Ratio: -17% (up=1, down=2)